One Analyst Shares This $.25 NYSE Stock Has Approximately 1,500% Potential Upside (Multiple Price Targets)
> Full Report Released 9:30AM EST Today <
(Do Right Now) SMS Update System Sign-up Info Below
It's Time To Focus In On My Next Big Breakout Idea...
This new profile is a clinical-stage biopharmaceutical company trading on the NYSE.
Current analyst provided price targets are painting crosshairs of tremendous upside potential on this company as it presently trades in the $.25 range.
The biggest price target is currently giving this company an approximate potential upside of 1,500%. Wow!
You know now that I think about it, many details of this new stock idea are starting to remind me of another recent runner with a significant analyst price target in NASDAQ champ CTXR.
Released in December at approximately $.60, biopharma stock CTXR cruised $.65 in one week for a high of $1.25 for a 108% surge.
With multiple analysts also chiming in on this new stock profile, it could be the next big breakout idea of 2020. You will not want to miss it!
To make sure you get this profile at 9:30AM EST today, do this right now: